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INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac ar-
rhythmia. Prevalence of AF is 3% of the general population 
and still increasing. One of the most important thing about 
treatment of patients with atrial fibrillation is prevention 
of thromboembolic complications [1−3]. Anticoagulation 
therapy by VKA (warfarin, acenocoumarol) or NOAC 
(apixaban, dabigatran, edoxaban, rivaroxaban) are highly 
effective however may cause severe bleeding complications 
especially in patients with coagulation or vascular disorders 
[4, 5]. One of the vascular disorders is Osler-Weber-Rendu 
disease (OWRD) known as hereditary hemorrhagic telan-
giectasia (HHT) [6].
CASE PRESENTATION 
We present a case report concerning a 79-year-old woman 
with atrial fibrillation and Osler-Weber-Rendu disease. The 
syndrome was diagnosed on the basis of clinical Curacao 
criteria : recurrent severe epistaxis, presence of skin and 
mucosa lesions (telangiectasias of face, ears, lips, hands, 
tongue) and positive family history (first-degree relatives 
with diagnosed OWR disease) (Fig. 1 A−C) [7]. Genetic 
testing had not been performed. Comorbidities included 
atherosclerosis, arterial hypertension, type 2 diabetes , 
chronic heart failure, chronic kidney disease and hypo-
thyroidism. Additionally, the patient had a history of small 
bowel resection due to mesenteric embolism.
 In March 2015 she was hospitalized in the Department 
of Internal Medicine because of heart failure symptoms. 
During hospitalization atrial fibrillation was diagnosed 
for the first time. Due to high thromboembolic risk 
(CHA2DS2-VASc score of 9) oral anticoagulant was 
recommended. After hematologic consultation warfarin 
was introduced. The patient was also qualified for urgent 
pacemaker implantation due to sinus sick syndrome. After 
the procedure oral anticoagulation was sustained.
In July 2015 she was readmitted to the Department of 
Internal Medicine due to extensive epistaxis. Laboratory 
tests revealed severe anemia requiring blood transfusions. 
Because of persistent nosebleeds anterior nasal packing and 
coagulation was performed. After a few days of observation 
the patient was discharged in good general condition.
Two weeks later she was hospitalized again for recur-
rent epistaxis. Laboratory tests showed INR of 7,3 despite 
proper use of warfarin and moderate anemia. The patient 
received vitamin K and cyclonamine along with supple-
mentation of iron, cobalamine and folic acid. Oral antico-
agulation was continued. She was referred to cardiology 
department to be evaluated for percutaneous closure of 
left atrial appendage (LAA).
Due to high thromboembolic and bleeding risk the 
patient was qualified for transcatheter LAA occlusion. 
Before the procedure transesophageal echocardiography 
(TEE) was done. TEE revealed windsock-shaped LAA 
with no thrombus inside. Based on the result of imaging 
examination (TEE) LAA morphology was determined to 
be suitable for occlusion with Watchman device. LAA clo-
sure was performed with three dimensional TEE guidance 
under general anaesthesia and a Watchman 30 mm LAA 
Closure Device was successfully implanted (Fig. 1D). The 
procedure and recovery were uneventful and after two days 
the patient was discharged home in good general condition. 
Dual antiplatelet therapy was prescribed. After 45 days 
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TEE showed proper position of device. In the following 
12months antiplatelet therapy was reduced to low-dose 
aspirin (75 mg), which was well tolerated. In long-term 
observetion no thromboembolic event, epistaxis or severe 
bleeding have occurred. 
CONCLUSIONS
Osler-Weber-Rendu disease (OWRD) also known as 
hereditary hemorrhagic telangiectasia (HHT) is a rare 
autosomal dominant vascular dysplasia which causes 
telangiectases and arteriovenous malformations of skin, 
mucosa, and internal organs. The prevalence of OWRD in 
Europe is 1 case per 5000 to 8000 population and has been 
estimated to range from 1:200 to 1:100000 worldwide. The 
clinical diagnosis is based on the Curaçao criteria include 
epistaxis, telangiectases, visceral lesions and family history 
(a first-degree relative with HHT). Three or four criteria 
must be present [6−8]. The most common presentation 
of OWRD are extensive epistaxis which can lead to severe 
anemia requiring blood transfusion [9−11].
 Atrial fibrillation (AF) is the most common arrhythmia 
with incidence estimated at 3% of the general population. 
Thromboembolic events are the most severe complica-
tions of this arrhythmia. AF is associated with fivefold 
higher risk of ischemic stroke [1−3]. Management of AF 
patients is aimed at prevention of these complications. In 
order to stratify the individual thromboembolic risk the 
CHA2DS2-VASc score is used. In patients with high risk 
of thromboembolism events (a CHA2DS2-VASc score ≥2) 
the anticoagulation therapy is indicated [12, 13]. 
Left atrial appendage (LAA) is the main site of thrombi 
formation. In patients with non-valvular AF over 90% of 
blood cloths originate from LAA [14, 15]. Non-pharma-
cological methods of ischemic stroke prevention include 
surgical exclusion or percutaneous closure of LAA. Accord-
ing to the European Society of Cardiology (ESC) guide-
lines this procedure may be considered in patients with 
non-valvular AF, high risk of stroke and contraindications 
for long-term oral anticoagulation therapy (IIb, level C) 
[12, 16]. The randomized trials showed that percutaneous 
LAA closure and VKA treatment (warfarin), were similarly 
effective in stroke prevention [17−20].
Patients with AF, high risk of stroke and concomitant 
vascular disorders like OWRD belong to the group at high 
risk of bleeding complications. This population is extremely 
problematic with respect to proper anticoagulation - due 
to complications up to 50% of patients discontinue this 
therapy [21]. The most commonly used oral anticoagulants 
are vitamin K antagonist (VKA). Currently there is no data 
from clinical trials assessing the use of non-vitamin K oral 
anticoagulants (NOAC) in patients with HTT.
Fig 1: A. Telegiecstasias of face, ears and lips; B. Lesions of face, lips and tongue, C. Telegiecstasias of hand; D. LAA occlusion by Watchman Device 27 mm.
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At present there are no recommendations regarding 
treatment of patients with both HHT and AF. There are 
no specific guidelines that include the best therapeutic 
strategy in this population. 
The case that we present shows a clinical dilemma. Case 
reports available via Pubmed report considerable reduction 
of bleeding complications in patients with AF and HHT who 
underwent percutaneous LAA occlusion [22, 23]. Further 
multicenter and randomized clinical trials are required to es-
tablish all risks and benefits of LAAC in this group of patients. 
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